Role of oncogenic REG? in cancer - 27/10/20
pages | 6 |
Iconographies | 2 |
Vidéos | 0 |
Autres | 0 |
Graphical abstract |
Highlights |
• | REG gamma (REGγ) belongs to a member of the 11S family of proteasome activators. |
• | REGγ regulates tumor proliferation, migration, angiogenesis, cell cycle, and metastasis. |
• | REGγ elicits its biological functions by activating several signaling pathways. |
• | REGγ may be served as a potential cancer biomarker for clinical diagnosis and therapy. |
• | REGγ may be a novel therapeutic target for multiple human cancers. |
Abstract |
Cancer is a critical global health-care problem with limited therapeutic options. Since cancers are life-threatening illnesses, the identification of a promising oncotarget and its clinical correlates are relevant. Mounting evidence has emerged indicating that REG gamma (REGγ), a member of the 11S proteasome activators, plays a pivotal role in the development of multiple human cancers. However, an elaborate summary on the association between REGγ and cancer is still lacking. In this Review, we discuss how REGγ, through its ATP- and ubiquitin-independent manners, represents a promising cancer biomarker and therapeutic oncotarget for multiple human cancers. Aberrant REGγ expression closely associated with tumorigenesis attributes to its biological functions for controlling and regulating cell cycle, proliferation, migration, invasion, angiogenesis, and metastasis of the cancer cells by degrading proteins of cytosol and nucleus in the eukaryotic cells. REGγ serves as a molecular switch to activate multifarious oncogenic signaling pathways, such as MAPK/p38, TGF-β/Smad, and Wnt/β-catenin. The review describes that targeting REGγ may provide new diagnostic and therapeutic applications in cancer.
Le texte complet de cet article est disponible en PDF.Keywords : REGγ, Cancer, Pathogenesis, Oncogene, Biomarker
Plan
Vol 130
Article 110614- octobre 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?